

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
23 December 2021 (23.12.2021)



(10) International Publication Number  
**WO 2021/257456 A1**

(51) International Patent Classification:

A61K 31/454 (2006.01) A61P 9/04 (2006.01)

A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2021/037230

(22) International Filing Date:

14 June 2021 (14.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/039,438 15 June 2020 (15.06.2020) US

63/042,512 22 June 2020 (22.06.2020) US

(71) Applicant: **MYOKARDIA, INC.** [US/US]; 1000 Sierra Point Parkway, Brisbane, California 94005 (US).

(72) Inventors: **TAMBY, Jean-Francois**; c/o MyoKardia, Inc., 1000 Sierra Point Parkway, Brisbane, California 94005 (US). **EDELBERG, Jay M.**; c/o MyoKardia, Inc., 1000 Sierra Point Parkway, Brisbane, California 94005 (US). **KURIO, Gregory Howard Takeo**; c/o MyoKardia, Inc., 1000 Sierra Point Parkway, Brisbane, California 94005 (US). **KELLY, Cynthia Lyle**; c/o MyoKardia, Inc., 1000 Sierra Point Parkway, Brisbane, California 94005 (US). **YANG, Chun**; c/o MyoKardia, Inc., 1000 Sierra Point Parkway, Brisbane, California 94005 (US). **HENZE, Marcus Patrick**; c/o MyoKardia, Inc., 1000 Sierra Point Parkway, Brisbane, California 94005 (US). **DEL RIO, Carlos L.**; c/o MyoKardia, Inc., 1000 Sierra Point Parkway, Brisbane, California 94005 (US). **ANDERSON, Robert Lee**; c/o MyoKardia, Inc., 1000 Sierra Point Parkway, Brisbane, California 94005 (US). **SUMANDEA, Marius P.**; c/o MyoKardia, Inc., 1000 Sierra Point Parkway, Brisbane, California 94005 (US). **GANJU, Jitendra**; c/o GANJU CLINICAL TRIALS, LLC, 45 Cleary Court, #7, San Francisco, California 94109 (US).

(74) Agent: **LI, Z. Ying** et al.; Steptoe & Johnson LLP, 1330 Connecticut Avenue, N.W., Washington, District of Columbia 20036 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: TREATMENT OF ATRIAL DYSFUNCTION

(57) Abstract: Provided herein are methods, uses, and compositions for treating AF in a patient, such as a patient exhibiting heart failure with reduced ejection fraction.

WO 2021/257456 A1